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Summary
 
In acute promyelocytic leukemia (APL) patients, retinoic acid (RA) triggers differentiation while
arsenic trioxide (arsenic) induces both a partial differentiation and apoptosis. Although their
mechanisms of action are believed to be distinct, these two drugs both induce the catabolism of
the oncogenic promyelocytic leukemia (PML)/RAR
 
a 
 
fusion protein. While APL cell lines resis-
tant to one agent are sensitive to the other, the benefit of combining RA and arsenic in cell culture
is controversial, and thus far, no data are available in patients. Using syngenic grafts of leukemic
blasts from PML/RAR
 
a
 
 transgenic mice as a model for APL, we demonstrate that arsenic induces
apoptosis and modest differentiation, and prolongs mouse survival. Furthermore, combining ar-
senic with RA accelerates tumor regression through enhanced differentiation and apoptosis. Al-
though RA or arsenic alone only prolongs survival two- to threefold, associating the two drugs
leads to tumor clearance after a 9-mo relapse-free period. These studies establishing RA/arsenic
synergy in vivo prompt the use of combined arsenic/RA treatments in APL patients and exem-
plify how mouse models of human leukemia can be used to design or optimize therapies.
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A
 
cute promyelocytic leukemia (APL)
 
1
 
 is specifically as-
sociated with a t(15;17) translocation which generates
a PML/RAR
 
a 
 
fusion between the gene of a nuclear pro-
tein, promyelocytic leukemia (PML), and that of a tran-
scription factor, the retinoic acid receptor 
 
a
 
 (RAR
 
a
 
). RA
and RAR
 
a
 
 are believed to contribute to myeloid differen-
tiation (1, 2). PML, through its association with nuclear
matrix domains of unknown function (PML nuclear bod-
ies, NBs [3]), was shown to suppress growth (4–6) and
to induce apoptosis (7–9). Some PML/RAR
 
a
 
 transgenic
mice develop a disease that strikingly resembles APL, estab-
lishing that PML/RAR
 
a
 
 can initiate the leukemic process
(10). PML/RAR
 
a
 
 was shown to block myeloid differenti-
ation (11), most likely through the impairment of RA re-
sponse. The latter appears to result from the tighter binding
to PML/RAR
 
a
 
 compared with RAR
 
a
 
 of corepressor
proteins involved in transcriptional silencing (12, 13). Con-
versely, PML/RAR
 
a
 
 also delocalizes PML from NBs (14–
17) and blocks apoptosis (11, 18, 19). Hence, in this model,
PML/RAR
 
a
 
 exerts a double dominant-negative effect on
the function of both RAR
 
a
 
 and PML proteins (20, 21).
RA and arsenic trioxide (arsenic) were shown to be clin-
ically effective in APL treatment through the induction of
differentiation and apoptosis, respectively (22, 23). In non-
APL cells, RA binds to RARs, activating transcription of
target genes, whereas arsenic alters the traffic of PML pro-
teins, enhancing their NB association as well as their apop-
totic properties (7, 24, 25). In addition, in APL cells, both
drugs degrade PML/RAR
 
a
 
 (24–27). It is not yet clear
which of the actions of these two drugs, on the fusion or
on the normal RAR
 
a
 
 or PML alleles, is responsible for
their distinct biological effects (differentiation versus apop-
tosis). These drugs would be expected to synergize, since
cell lines resistant to one agent remain sensitive to the other
(28–30). However, current evidence obtained
 
 
 
in vitro
 
 
 
is
conflicting (28–30). In this report, we have established
an in vivo APL model by transplanting leukemic blasts
 
from PML/RAR
 
a
 
 transgenic mice. Although arsenic or
RA only modestly prolongs survival, combining the two
 
1
 
Abbreviations used in this paper:
 
 APL, acute promyelocytic leukemia;
arsenic, arsenic trioxide; NB, nuclear body; PML, promyelocytic leuke-
mia; RA, retinoic acid; TUNEL, terminal deoxynucleotidyltransferase–
mediated dUTP nick end labeling. 
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agents induces faster tumor regression and sharply prolongs
survival. These studies exemplify how mouse models of hu-
man leukemia can be used to optimize therapies and prompt
the use of combined arsenic/RA treatments in APL patients.
 
Materials and Methods
 
Transplantation of Leukemia and Arsenic/RA Treatments.
 
Leu-
kemic cells were isolated from bone marrow and spleen of leuke-
mic hMRP8-PML/RAR
 
a
 
 transgenic mice (leukemia 935) as
described (10), by flushing RPMI medium through long bones
and collecting exudates from spleen. In vitro, spleen cells were
cultured in RPMI medium supplemented with 10% FCS and 2%
pockweed mitogen spleen–conditioned medium and were left
untreated or were treated with 1 
 
m
 
M RA, 1 
 
m
 
M As
 
2
 
O
 
3
 
 (Sigma
Chemical Co.), or both.
Leukemias were propagated by injecting blasts (10
 
7
 
 viable
hematopoietic cells) into the tail vein of 6–7-wk-old syngenic
FVB-NICO mice. Animal handling was done according to the
guidelines of institutional animal care committees. Mice implanted
with leukemic cells were randomly assigned to either type of
treatment. RA was administrated to leukemic mice by subcuta-
neous implantation of a 21-d release pellet containing 10 mg
ATRA (Innovative Research of America). A stock solution of
330 mM As
 
2
 
O
 
3
 
 was prepared by diluting the powder in 1 M
NaOH, then a dilution in Tris-buffered saline (TBS) was admin-
istered by daily intraperitoneal injection at the concentration of
5 
 
m
 
g/g mice. Control mice were treated with placebo pellets or
intraperitoneal injections of TBS.
 
Histological and Cytological Analyses.
 
Specimens of spleen,
liver, and lung were cut into three parts and immediately pro-
cessed for snap freezing in liquid nitrogen or fixations. Specimens
of long bones were fixed in formaldehyde, decalcified in 10% ni-
tric acid, and further processed for paraffin embedding. Spleen,
liver, and lung were either fixed in alcohol-formaldehyde-acetic
acid reagent (AFA; Carlo Erba Laboratories), paraffin embedded
and stained with hematoxylin-eosin and May-Grünwald-Giemsa,
or fixed in 2.5% glutaraldehyde in cacodylate buffer and epon
embedding for electron microscopic examination. The extent of
the leukemic infiltrate was assessed on paraffin sections. The dif-
ferentiation of the leukemic cells was assessed by combining cyto-
logical and histological stains, immunofluorescent staining of
cryocut sections with a rat anti–mouse CD11b antibody (Phar-
Mingen) and electron microscopic analysis. In situ cell death was
studied by morphological analysis on paraffin sections, electron
microscopic grids, and by terminal deoxynucleotidyltransferase–
mediated dUTP nick end labeling (TUNEL) assays (reagents from
Boehringer Mannheim), both on paraffin and cryocut sections.
 
Results
 
Leukemic Cells from PML/RAR
 
a
 
 Transgenic Mice Are Ar-
senic Sensitive.
 
hMPR8-PML/RAR
 
a
 
 transgenic mice de-
velop transplantable leukemias which differentiate both in
vivo
 
 
 
and in vitro upon RA exposure (10). To test their
sensitivity to arsenic in vitro, leukemic cells were isolated
from spleen or bone marrow of moribund animals and cul-
tured in the presence or absence of arsenic. Little apoptosis
and no differentiation were observed by TUNEL or cyto-
logical examinations. Conceivably, growth factors present
in conditioned media may block apoptosis, as demonstrated
 
in other cellular settings. However, both arsenic and RA
induced PML/RAR
 
a
 
 degradation (data not shown), as
shown previously in APL cell lines (25, 26), confirming
that degradation of the fusion protein does not suffice to
trigger arsenic-induced apoptosis (30).
Syngenic FVB mice were then injected with 10
 
7
 
 leukemic
cells. Transplantation was always successful, as all animals
died with an intraexperimental variation of 
 
,
 
1 wk, generally
in 30–50 d. In dose–response experiments, mice were treated
for 1 mo with daily injections of arsenic or TBS 4 d after
leukemia engraftment. Although 1 
 
m
 
g/g body wt arsenic
daily yielded no tumor regression upon killing, 10 
 
m
 
g/g led
to many early deaths, presumably of toxic origin (patholog-
ical examination revealed some hepatic toxicity and wide-
spread pulmonary edema). However, with 5 
 
m
 
g/g, arsenic-
treated animals showed greatly reduced leukemic infiltrate
of the organs analyzed. As nontransplanted mice treated
with this same dose for the same length of time also showed
no evidence for toxicity, a daily dose of 5 
 
m
 
g/g was used
thereafter. Despite the much higher doses used in mice
compared with humans, the circulating arsenic levels were
in the range of those present in arsenic-treated APL pa-
tients (31; data not shown). In pilot survival experiments
where mice were treated 4 d after transplantation for 38 d,
the 10 arsenic-treated mice lived significantly longer than
the 10 controls (mean: 124 
 
6
 
 6 vs. 50 
 
6
 
 4 d). Altogether,
our results demonstrate that leukemic cells from PML/
RAR
 
a
 
 transgenic mice are arsenic sensitive in vivo.
 
RA and Arsenic Synergize to Induce Tumor Regression.
 
We
have previously shown in cell lines that arsenic and RA ap-
pear to synergize for both differentiation and apoptosis (30),
although this has been disputed (22, 28). To test the possible
synergy between these two agents in vivo, we evaluated
their effects on the regression of established leukemias.
Hence, for this set of experiments, leukemias were allowed
to develop for 20–25 d before therapy. Leukemic mice were
then randomly assigned to treatment with arsenic, RA, both,
or vehicle for 4 or 8 d and killed (two mice per treatment
and time point). In three different experiments, RA or ar-
senic treatments reduced spleen weight and liver infiltration,
whereas their association completely normalized the macro-
scopic appearance of these organs (not shown).
Microscopic examination of hematoxylin-eosin–stained
sections of bone marrow, spleen, and liver from these ani-
mals confirmed this observation. In the absence of therapy,
massive leukemic infiltration was evident in all three or-
gans. In particular, the bone marrow was strictly mono-
morphic, consisting of promyelocyte-like cells that retained
immature features such as basophilic cytoplasm (Fig. 1 A).
As reported previously, RA caused the rapid differentia-
tion of leukemic cells into polymorphonuclear leukocytes.
In the bone marrow, 4 d of RA treatment induced a drastic
reduction of the cellular density with reappearance of some
adipocytes (Fig. 1 B, and data not shown). Nevertheless,
the marrow remained monomorphic, almost exclusively
composed of polymorphonuclear cells (arrowheads, Fig. 1
B). After 8 d of RA, normal hematopoiesis was restored,
with a large number of erythroblasts and a decrease in gran- 
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ulocytes compared with nonleukemic bone marrow (Fig.
1 A). In the liver of animals treated with RA for 4 d, small
remaining tumor masses consisting of maturating myeloid
cells were found around vessels of the portal tracts or cen-
trilobular veins (see arrows in Fig. 2 and Fig. 5 A). Leuke-
mic infiltration of the parenchyme was dramatically reduced
at day 8 (not shown). The spleen contained a large number
of granulocytes at both 4 and 8 d, but the leukemic infil-
Figure 1. Arsenic and RA in-
duce tumor regression. (A) Cy-
tological analysis by May-Grün-
wald-Giemsa staining of the
bone marrow from leukemic
mice left untreated or treated
with RA, arsenic, or both for 8 d.
N, normal control; Ø, leukemic
untreated control; RA, RA-
treated; As, arsenic-treated;
RA1As, dual therapy. Scale
bars, 10 mm. The bone marrow
of the untreated animals is
monomorphic. Note that in
RA-treated animals, restoration
of normal bone marrow is ac-
companied by a quantitative loss
in granulocytes. Arsenic-treated
cells exhibit an altered aspect of
chromatin. Activated histiocytes
with images of phagocytosis
(bottom right) are abundant in
dual-treated cells. (B) Histo-
pathological analysis of bone
marrow of leukemic mice left
untreated or treated with arsenic,
RA, or both for 4 d. RA induces
granulocytic differentiation (ar-
rowheads), arsenic induces apop-
totic images (arrows) and differ-
entiation (arrowheads), and their
association induces the reappear-
ance of normal marrow elements
such as erythroblasts (arrows). 
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trate rapidly diminished (not shown). These observations
confirm previous analyses of these animals (10).
4 d after arsenic treatment, some cells with a condensed
nucleus have apoptotic-like features (arrows, Fig. 1 B),
while partly differentiated cells with indented nuclei were
also observed (arrowheads, Fig. 1 B). At 8 d, the bone mar-
row remained quite monomorphic, consisting of myeloid
cells with an altered chromatin clearly distinct from that of
untreated blasts (Fig. 1 A). In the liver of untreated animals,
leukemic blasts infiltrate the parenchyme as very large peri-
vascular masses associated with smaller aggregates of leuke-
mic cells that obstructed sinusoids (Fig. 2, and see Fig. 5 A).
In the leukemic blasts from the small intrasinusoid aggre-
gates, arsenic induced morphological changes such as the
appearance of indented nuclei and apoptosis-like nuclear
condensation (arrowheads and arrows, Fig. 2). As a result of
arsenic therapy, only large perivascular masses consisting of
differentiated/apoptotic cells remain after the first week (not
shown). Nevertheless, at both time points, the reduction in
tumor mass was less drastic than that observed with RA.
Treatment with both RA and arsenic led to a much
faster decrease in the leukemic population. In the marrow,
islets of normal erythroblasts were already clearly visible 4 d
after treatment, which was not the case with the single
agent treatments (arrows, Fig. 1 B). After 8 d, the bone
marrow was normal, with abundant erythroblasts and mega-
karyocytes (Fig. 1 A). Interestingly, we found numerous
activated phagocytes with internalized granulocytes, which
could account for the relative deficit in granulocytes com-
pared with nonleukemic marrow. 4 d after treatment, the
liver presented only very small remaining aggregates of leu-
kemic cells around large vessels (Fig. 2, and see Fig. 5 A). At
8 d, both liver and spleen appeared tumor-free (not shown).
 
Mechanisms of RA/Arsenic Synergy.
 
Ultrastructural anal-
ysis of liver sections was undertaken to analyze the mor-
phology of leukemic cells after 4 d of therapy (Fig. 3). In
livers of untreated leukemic animals, blasts (with lobulated
nuclei and dense cytoplasm with some granulations) were
clearly visible among hepatocytes and endothelial cells.
Upon RA treatment, differentiating myeloid cells resem-
Figure 3. Electron micro-
scopic analysis of liver leukemic
infiltrates during various thera-
pies. Ø, leukemic untreated con-
trol blasts at low (left) and high
(right) magnification; RA, RA-
treated cells showing a differenti-
ating myeloid cell; As, arsenic-
treated cells showing apoptotic
cells with moderately condensed
chromatin but no nuclear frag-
mentation. Note the cytoplasmic
lysis. RA1As, dual therapy
showing a rare apoptotic granu-
locyte being phagocytized by a
Kupffer cell. Scale bars, 1 mm.
 
Figure 2.
 
Histopathological analysis of livers after 4-d treatments as indicated. (Left) Low magnification. Arrows point to leukemic blasts. (Right) High
magnification. Ø, leukemic untreated control. RA: arrows point to differentiating blasts; arsenic (As): arrowheads indicate differentiating blasts, and arrows
point to apoptotic nuclei; RA
 
1
 
As: arrows point to altered hepatocytes.  
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bling granulocytes with fragmented nuclei and dense chro-
matin were found in the vascular space. Interestingly,
arsenic treatment led to the appearance of many cell rem-
nants, often consisting of naked nuclei, or with profound
cytoplasmic alterations including large vacuoles and dis-
rupted plasma membrane. However, the chromatin appeared
moderately condensed at the nuclear periphery. The nu-
clear indentations and the presence of cytoplasmic granula-
tions are strongly suggestive for the leukemic origin of
these cells. We have recently demonstrated that PML trig-
gers a caspase-independent cell death (7). The aspects of
arsenic-treated APL blast unraveled here (Fig. 3) are highly
reminiscent of PML-induced death, consistent with the
idea that one of the effects of arsenic is to trigger PML-
mediated death. Dual-treated specimens harbored very few
hematopoietic cells, but on some occasions, images of apop-
totic granulocyte phagocytosis were observed (Fig. 3). Al-
together, these analyses confirm that RA induces differen-
tiation whereas arsenic triggers a cell death process not
associated with major nuclear alterations.
To quantify differentiation and apoptosis, sections were
stained with CD11b for assessment of differentiation (22,
29, 30) and a TUNEL assay was used for assessment of apop-
tosis. Either RA, arsenic, or both treatments sharply in-
duced CD11b expression in the infiltrated liver at day 4
(Fig. 4), as shown previously for APL blasts in patients (29).
In the liver, a basal level of TUNEL positivity was noted in
the leukemic cells of untreated mice (Fig. 5 A), consistent
with high rates of spontaneous apoptosis of tumor cells in
vivo. Arsenic sharply enhanced TUNEL positivity, particu-
larly in the small leukemic aggregates in the liver sinusoids
(Fig. 5 A). With RA treatment, intense TUNEL positivity
was found in the red pulp of spleen, whereas liver was
completely negative, suggesting that RA triggered the mi-
gration of differentiated leukemic cells to the spleen where
they underwent apoptosis. Double RA/arsenic therapy led
to an even more dramatic enhancement of TUNEL posi-
tivity in the spleen (Fig. 5 B), suggestive of accelerated dif-
ferentiation and migration to this site.
 
RA and Arsenic Cooperate to Induce Complete Remissions.
 
To see whether RA and arsenic also influenced survival, 20
mice were transplanted, allowed to engraft for 12 d, and
were then left untreated or were treated with arsenic, RA,
or both until the first mouse in the control group died (40 d).
Hence, mice were treated for 28 d, and survival was moni-
tored. After arsenic therapy, all animals eventually died
within a narrow time range (80 d; Fig. 6 A), as reported
above with a shorter implantation time before treatment. In
the case of RA therapy, relapses were more scattered but all
animals died between 78 and 220 d after transplantation. In
striking contrast, all double-treated animals were alive 9 mo
after transplantation. The log–rank test demonstrates that dif-
ferences between the survival of these four groups are highly
statistically significant (
 
P
 
 5 
 
0.0001). Moreover, dual RA and
arsenic therapy was significantly better than RA alone (
 
P
 
 5
 
0.002). These observations are consistent with the synergistic
effects of RA and arsenic on tumor regression.
To know whether the double treatment had actually
eradicated the leukemia, surviving animals were killed at
day 280 after transplantation. Microscopic examination of
the bone marrow and spleen showed no leukemic infiltrate
(not shown). The presence of leukemic cells was molecu-
Figure 4. Arsenic and RA in-
duce differentiation. Immuno-
fluorescence analysis of liver sec-
tions from mice treated with
vehicle (Ø), RA, arsenic (As), or
both (RA1As) for 4 d. Both
therapies induce CD11b expres-
sion in vivo, as suggested previ-
ously by in vitro studies. 
1049
 
Lallemand-Breitenbach et al.
 
larly assessed by PCR amplification of the leukemia-
specific PML/RAR
 
a
 
 fusion gene. In splenic DNA from all
four mice tested, no amplification products were found
with a nested PCR assay that detects 1 leukemic cell in
1,000–10,000 cells (32; data not shown), whereas the
mouse p13 gene was amplified in all four cases. Thus, after
dual RA and arsenic therapy, leukemic cells have become
undetectable.
 
Discussion
 
This report presents evidence that two drugs that specifi-
cally target the PML/RAR
 
a
 
 fusion protein in APL coop-
erate in vivo to induce tumor regression and dramatically
prolong survival. This model offers the advantage that it
closely mimics the APL situation: a population of malignant
cells is present in an immunocompetent organism, and only
this population is PML/RAR
 
a
 
 positive, in contrast to trans-
Figure 5. Apoptosis during
RA or arsenic therapy. TUNEL
analysis of livers (A) and spleens
(B) from animals treated as in the
legend to Fig. 2 for 4 d. Apop-
totic nuclei stain in red; normal
cell nuclei stain in blue. Arsenic
(As) induces blast apoptosis in
the spleen as well as in the liver,
whereas RA induces little apop-
tosis in the liver, but dramatically
increases the rate of cell death in
the spleen. The association of the
two (RA1As) greatly increases
apoptosis in the spleen. RA-
induced tumor regression is clearly
visible (A). Ø, leukemic un-
treated control. 
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genic animals where all myeloid cells express the fusion pro-
tein. The behavior of the leukemic cells versus the nontrans-
formed hematopoiesis is much better assessed in this setting,
and immune response against the leukemia can occur.
Despite previous claims (28), it seems logical that these
two drugs which target an oncogene for degradation through
distinct pathways cooperate rather than antagonize, con-
firming our previous findings in vitro
 
 
 
(30). A double domi-
nant-negative model was proposed to explain APL patho-
genesis, whereby PML/RAR
 
a
 
 blocks the functions of the
normal RAR
 
a
 
 (differentiation) and the normal PML (apop-
tosis) proteins (20). Apart from inducing PML/RAR
 
a
 
degradation, RA transcriptionally activates RAR, promot-
ing differentiation. In addition, RA induces RAR
 
a
 
 degra-
dation (30; our unpublished observations). Similarly, arsenic
induces PML/RAR
 
a
 
 degradation. Arsenic also targets PML
onto NBs, enhancing its proapoptotic properties (7) and sub-
sequently promoting PML degradation (25). Hence, in this
double dominant-negative model, PML/RAR
 
a
 
 degrada-
tion by one agent should favor the action of the other and
vice
 
 
 
versa
 
 
 
(Fig. 6 B). Our results, both
 
 
 
in vitro and in vivo
showing enhanced differentiation and apoptosis with dual
treatments, are consistent with this model. Nevertheless, it is
also possible that arsenic modifies the function of RAR
 
a
 
, as
it enhances RAR
 
a
 
 phosphorylation (25) (which was re-
cently shown to modify its function [33, 34]) and induces
RAR
 
a
 
 catabolism (30). Together with PML/RAR
 
a
 
 degra-
dation, arsenic’s effects on RAR
 
a
 
 could account for the
moderate differentiation induced by this agent. Moreover,
the most striking synergy in the double treatments concerns
differentiation, suggesting that arsenic enhances RA’s effects
more than the reverse.
Some toxicity occurred, but under our conditions it was
acceptable and never led to deaths. Arsenic alone was hepa-
totoxic as assessed by moderate edema and steatosis, whereas
dual treatment induced some hepatocyte apoptosis sug-
gested by dense rims of nuclear heterochromatin and nu-
clear condensation on electron micrographs (not shown;
see also arrows, Fig. 2). Some endothelial toxicity was also
noted with dual treatment. However, the absence of major
toxicity in a pilot case of dual treatment in a relapse APL
patient (Dombret, H., and L. Degos, personal communi-
cation) suggests that toxicity is unlikely to limit the associa-
tion of these two drugs.
In our experimental model, mice relapse quickly after sin-
gle treatment discontinuation. One obvious possibility is that
our treatments were too short. Alternatively, the therapeutic
route (subcutaneous for RA, intraperitoneal for arsenic), dif-
ferent from that used in patients (oral for RA, intravenous
for arsenic), may not have been optimal. Nevertheless, in
human APL, resistance to RA or arsenic as single agents is
quite rapid (31, 35, 36). In addition, rate of spontaneous re-
sistance to RA or arsenic of APL cell lines is also high (30,
37). Such high intrinsic resistance of APL cells to these
agents could account for the high incidence of relapses
with single agent therapy. Here, the apparent eradication of
the leukemic clone may reflect the direct differentiating/
proapoptotic properties of these two agents. Alternatively,
the small number of cells resistant to both RA and arsenic
may be eradicated by NK cell activity or by an immune re-
sponse against the graft. In that sense, the necrotic-like death
of arsenic-treated APL cells (Fig. 3) could induce an antileu-
kemia immune response, as proposed in another setting (38).
To our knowledge, these studies represent the first ex-
ample of clinical trials in a mouse model derived from a
transgenic system of a human leukemia. Current protocols
use induction therapies based on the simultaneous or sequen-
tial use of RA and chemotherapy (39). To date, arsenic is
used as a single agent, principally in relapse APL patients
(31, 35). The dramatic synergy between these two agents
has obvious therapeutic indications: eradication of the leu-
kemic clone in dual-treated animals clearly favors the use of
arsenic as a first line drug, suggesting that combined thera-
pies should be assessed in APL patients.
Figure 6. (A) Survival curve of leukemic mice left untreated (n) or
treated for 28 d with RA (d), arsenic (h), or both (bold line). The ex-
periment was stopped at month 9. Although single treatments only
prolong survival, combining arsenic and RA promotes long-term re-
mission. (B) Model for the synergism between RA and arsenic (adapted from reference 20). Arsenic and RA induce two distinct pathways of PML/RARa
degradation, allowing restoration of PML and RARa normal functions. Arsenic enhances PML cell death by retargeting the protein onto NBs, and RA
activates its receptor to promote myeloid differentiation. PML/RARa degradation by one agent likely facilitates the action of the other and vice versa.1051 Lallemand-Breitenbach et al.
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